The Latest Innovation in Glaucoma Management: DURYSTA™

The Latest Innovation in Glaucoma Management: DURYSTA™



DURYSTA™ (bimatoprost implant) is a prostaglandin analog indicated for the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension (OHT).

It is believed to lower IOP in humans by increasing the outflow of aqueous humor through both the trabecular meshwork (conventional) and uveoscleral routes (unconventional). DURYSTA™ is preloaded into a single-use, DDS applicator to facilitate injection of the rod-shaped implant directly into the anterior chamber of the eye.

The most common ocular adverse reaction in patients with open-angle glaucoma (OAG) or ocular hypertension (OHT) is conjunctival hyperemia. Other common ocular adverse reactions include foreign body sensation, eye pain, photophobia, conjunctival hemorrhage, dry eye, eye irritation, increased intraocular pressure, corneal endothelial cell loss, blurring of vision, and iritis.

Ophthalmic bimatoprost, including intracameral implant, has been reported to cause changes to pigmented tissues, such as increased pigmentation of the iris, which is likely to be permanent. The pigmentation change is due to increased melanin content in the melanocytes.

DURYSTA™ is contraindicated in patients with: active or suspected ocular or periocular infections; corneal endothelial cell dystrophy; prior corneal transplantation or endothelial cell transplants; absent or ruptured posterior lens capsule, due to the risk of implant migration into the posterior segment; hypersensitivity to bimatoprost or any other components of the product.

For more information, visit https://www.durystahcp.com /